Pacira BioSciences Plaintiffs Urged to Act Before Deadline
Important Notice for Pacira BioSciences Shareholders
The Gross Law Firm is announcing an urgent notice for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). There is a critical lead plaintiff deadline approaching on March 14, 2025, that shareholders need to be aware of. This opportunity allows those who purchased shares during the specified class period to potentially be appointed as lead plaintiffs in the ongoing lawsuit.
Details of the Class Period
Shareholders who acquired shares of PCRX from August 2, 2023, to August 8, 2024, are strongly encouraged to contact the Gross Law Firm regarding their eligibility for lead plaintiff status. While participation in the lead plaintiff role is optional, all shareholders may still recover losses from the class action suit without this appointment.
Allegations Against Pacira
The lawsuit is grounded in serious allegations pertaining to disclosures made by Pacira on August 9, 2024. Based on the court's findings, Pacira's U.S. Patent No. 11,033,495, which relates to Exparel—the product responsible for the majority of Pacira's revenue—was ruled invalid. This decision implies that eVenus is not infringing on Pacira's patent rights. Analysts have expressed concerns that this ruling could lead to increased competition from generic products, thereby heightening potential litigation costs moving forward.
Impact on Stock Value
This patent ruling had a profound effect on Pacira's stock. Following the announcement, the share price plummeted dramatically from a closing price of $22.36 on August 8, 2024, to a low of $11.70 the next day—a staggering drop of over 47%. Such a steep decline could have significant repercussions for investors holding shares during this turbulent period.
Acting Before the Deadline
As the deadline of March 14, 2025, approaches, shareholders are reminded to act without hesitation. Registering for participation in the class action lawsuit is a vital step toward securing potential recovery for their losses. The Gross Law Firm also provides supplementary services, including portfolio monitoring, to keep shareholders informed about the case's progress.
Why Choose the Gross Law Firm?
The Gross Law Firm stands out as a reputable class action law firm committed to upholding the rights of investors. Their goal is to protect against fraudulent actions and ensure that companies are held accountable for misleading practices. They advocate for the recovery of losses incurred when investors are misled by false statements or omissions that artificially inflate stock prices. Participation in this case comes without any costs or obligations to shareholders.
Contact Information
For more information or to participate in the class action lawsuit, shareholders can contact the Gross Law Firm directly.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the lead plaintiff deadline for Pacira BioSciences?
The lead plaintiff deadline is March 14, 2025.
Who should contact the Gross Law Firm?
Shareholders of Pacira BioSciences, Inc. who purchased shares between August 2, 2023, and August 8, 2024, should reach out.
What is the significance of the patent ruling?
The invalidation of Pacira's patent could lead to increased market competition and affect the company's revenue significantly.
How can shareholders participate in the class action?
Shareholders can register their information with the Gross Law Firm to participate and may also opt for lead plaintiff status.
What are the next steps for registered shareholders?
Once registered, shareholders will receive updates about the status of the case through portfolio monitoring services.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
